Total Payments
$412.54
2024 Payments
$117.32
Companies
4
Transactions
24
Medicare Patients
2,743
Medicare Billing
$152,339
Payment Breakdown by Category
Food & Beverage$412.54 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $412.54 | 24 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $156.76 | 9 | $0 (2024) |
| Novo Nordisk Inc | $125.44 | 8 | $0 (2024) |
| ABBVIE INC. | $94.73 | 5 | $0 (2024) |
| Xeris Pharmaceuticals, Inc. | $35.61 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $117.32 | 7 | Novo Nordisk Inc ($61.68) |
| 2023 | $121.46 | 7 | ABBVIE INC. ($63.91) |
| 2022 | $113.07 | 6 | Lilly USA, LLC ($92.10) |
| 2021 | $60.69 | 4 | Novo Nordisk Inc ($28.66) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Diabetes | ||||||
| 05/22/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Diabetes | ||||||
| 05/13/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $13.50 | General |
| Category: Diabetes | ||||||
| 02/20/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: NEUROSCIENCE | ||||||
| 02/15/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Diabetes | ||||||
| 01/29/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Diabetes | ||||||
| 01/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: Diabetes | ||||||
| 12/12/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: NEUROSCIENCE | ||||||
| 11/28/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: NEUROSCIENCE | ||||||
| 09/07/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Diabetes | ||||||
| 08/10/2023 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: Diabetes | ||||||
| 08/08/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: NEUROSCIENCE | ||||||
| 06/05/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: Diabetes | ||||||
| 05/03/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: Diabetes | ||||||
| 08/17/2022 | Lilly USA, LLC | TRULICITY (Drug), MOUNJARO | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: Diabetes | ||||||
| 06/24/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $36.12 | General |
| Category: Diabetes | ||||||
| 05/24/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: Diabetes | ||||||
| 04/12/2022 | Lilly USA, LLC | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $14.45 | General |
| Category: Diabetes | ||||||
| 03/10/2022 | Lilly USA, LLC | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Diabetes | ||||||
| 02/11/2022 | Lilly USA, LLC | EMGALITY (Drug), TRULICITY | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: Neuroscience | ||||||
| 10/07/2021 | Lilly USA, LLC | EMGALITY (Drug), TRULICITY | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Neuroscience | ||||||
| 09/24/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Diabetes | ||||||
| 08/04/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: Diabetes | ||||||
| 03/04/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 20 | 1,130 | 1,573 | $140,142 | $52,477 |
| 2021 | 24 | 1,613 | 2,668 | $218,512 | $99,862 |
Total Patients
2,743
Total Services
4,241
Medicare Billing
$152,339
Procedure Codes
44
All Medicare Procedures & Services
44 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 287 | 441 | $66,990 | $20,243 | 30.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 128 | 128 | $19,200 | $13,082 | 68.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 187 | 266 | $24,324 | $10,551 | 43.4% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 56 | 60 | $6,000 | $2,625 | 43.8% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 37 | 40 | $4,000 | $1,644 | 41.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 84 | 143 | $7,125 | $1,450 | 20.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 45 | 49 | $1,960 | $791.00 | 40.4% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 29 | 33 | $1,320 | $525.90 | 39.8% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 25 | 33 | $1,155 | $401.12 | 34.7% |
| 85610 | Blood test, clotting time | Office | 2022 | 15 | 76 | $1,368 | $324.19 | 23.7% |
| 82270 | Stool analysis for blood to screen for colon tumors | Office | 2022 | 49 | 49 | $1,225 | $213.13 | 17.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 12 | 30 | $750.00 | $203.22 | 27.1% |
| 81003 | Automated urinalysis test | Office | 2022 | 43 | 52 | $1,040 | $114.25 | 11.0% |
| 69209 | Removal of impacted ear wax by washing | Office | 2022 | 14 | 14 | $630.00 | $110.07 | 17.5% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2022 | 22 | 22 | $550.00 | $65.11 | 11.8% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2022 | 18 | 18 | $540.00 | $63.51 | 11.8% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2022 | 18 | 18 | $540.00 | $49.36 | 9.1% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 14 | 50 | $500.00 | $15.04 | 3.0% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2022 | 14 | 16 | $400.00 | $4.80 | 1.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 33 | 35 | $525.00 | $1.46 | 0.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 282 | 837 | $113,070 | $53,098 | 47.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 267 | 477 | $42,930 | $22,651 | 52.8% |
| 87811 | Sars-cov-2 covid19 w/optic | Office | 2021 | 95 | 116 | $11,600 | $4,759 | 41.0% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 208 | 341 | $17,050 | $3,271 | 19.2% |
| 90756 | Vaccine for influenza derived from cell cultures for injection into muscle, quadrivalent, antibiotic free, 0.5ml dosage | Office | 2021 | 82 | 82 | $2,460 | $2,326 | 94.6% |
About Garth Horn, FNP
Garth Horn, FNP is a Primary Care healthcare provider based in Houston, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2020. The National Provider Identifier (NPI) number assigned to this provider is 1033710272.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Garth Horn, FNP has received a total of $412.54 in payments from pharmaceutical and medical device companies, with $117.32 received in 2024. These payments were reported across 24 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($412.54).
As a Medicare-enrolled provider, Horn has provided services to 2,743 Medicare beneficiaries, totaling 4,241 services with total Medicare billing of $152,339. Data is available for 2 years (2021–2022), covering 44 distinct procedure/service records.
Ad
Practice Information
- Specialty Primary Care
- Location Houston, MS
- Active Since 11/04/2020
- Last Updated 11/22/2021
- Taxonomy Code 363LP2300X
- Entity Type Individual
- NPI Number 1033710272
Products in Payments
- MOUNJARO (Drug) $85.80
- Ozempic (Drug) $82.94
- UBRELVY (Drug) $64.82
- TRULICITY (Drug) $41.76
- GVOKE HYPOPEN (Drug) $35.61
- QULIPTA (Drug) $29.91
- EMGALITY (Drug) $29.20
- Rybelsus (Drug) $27.63
- RYBELSUS (Drug) $14.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Primary Care Doctors in Houston
Mrs. Mary Gibbens, Msn, Aprn, A-Gnp-C, MSN, APRN, A-GNP-C
Primary Care — Payments: $16,984
Primary Care $16,984
Ms. Meisha Smith, Fnp-C, FNP-C
Primary Care — Payments: $4,646
Primary Care $4,646
Nonye Nelson, Np, NP
Primary Care — Payments: $4,468
Primary Care $4,468
Hania Tofik
Primary Care — Payments: $3,937
Primary Care $3,937
Joanna Larson, Fnp, FNP
Primary Care — Payments: $3,277
Primary Care $3,277
Mrs. Natalie Greer, Aprn, APRN
Primary Care — Payments: $2,400
Primary Care $2,400